Endonovo Therapeutics Announces Significant Results From Study Showing 70% Reduction of Morphine Equivalent Dose and 2 Day Reduction of Length of Stay at Hospitals Using SofPulse®
27. Juli 2020 09:00 ET
|
Endonovo Therapeutics, Inc.
LOS ANGELES, July 27, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced that an investigator initiated study, authored by Dr. Samir...
Endonovo Therapeutics Announces Effectiveness of Registration of Equity Credit Line and Ceasing Variable Convertible Note Financing
21. Juli 2020 09:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, July 21, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announced the Company’s registration statement on Form S-1 relating...
Endonovo Therapeutics Announces First Quarter Fiscal 2020 Financial Results
15. Juni 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, June 15, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), today announces financial and operating results for the first quarter...
Endonovo Therapeutics Announces International Expansion with Distribution Agreement for SofPulse® in Taiwan, Republic of China
01. Juni 2020 10:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, June 01, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced the signing of a Sales and Strategic Partnership Agreement...
Endonovo Therapeutics Enters into $10 million Equity Line Agreement with Cavalry Fund
26. Mai 2020 08:18 ET
|
Endonovo Therapeutics, Inc.
Agreement Provides Flexible Access to Funding at a Lower Cost of Capital Los Angeles, CA, May 26, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company")...
Endonovo Therapeutics Announces Positive 2019 Fiscal Results
04. Mai 2020 08:15 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, May 04, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today reported financial results for fiscal year ended December 31, 2019. ...
Endonovo Therapeutics Announces Eight Additional Hospitals Approved Use of SofPulse® at Their Facilities
16. April 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, April 16, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced the addition of eight new hospitals Endonovo’s SofPulse®...
Endonovo Therapeutics seeks Intensive Care Unit Partners for Investigational Adjunctive Treatment for Severe Respiratory Inflammatory Complications for COVID-19 Patients.
25. März 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, March 25, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announces the intent to distribute of SofPulse®...
Endonovo to Donate SofPulse® Units for Investigational Use to Evaluate Inhibition of Inflammatory Symptoms Associated with COVID-19
16. März 2020 08:00 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, March 16, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced it will donate SofPulse® devices to Intensive Care Units...
Endonovo Therapeutics Files 8K With SEC Regarding SofPulse®
02. März 2020 07:30 ET
|
Endonovo Therapeutics, Inc.
Los Angeles, CA, March 02, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announced it has filed an 8K with the Securities and Exchange...